• It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Cassava Sciences: "They do have an Alzheimer's trial, but Lilly has an Alzheimer's formulation that is very good. And Lilly does have the edge on everybody else."

Mobileye Global: "...I think it's just too hard to tell, I'm going to stay away from it."

Sign up now for the CNBC Investing Club to follow Jim Cramer's every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Money Report

news 6 mins ago

Asian chip stocks fall on ASML's disappointing forecast, possible U.S. export cap

news 3 hours ago

Alibaba's international arm says its new AI translation tool beats Google and ChatGPT

Want to take a deep dive into Cramer's world? Hit him up!
Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com

Also on CNBC

• Jim Cramer explains why investors should wait out 'sloppy' post-earnings trading
• Cramer says reports from Wells Fargo and JPMorgan are 'good omens' for earnings season
• Cramer's Lightning Round: Uranium Energy is 'the real deal'

Subscribe to the CNBC YouTube Channel

Morning Squawk Newsletter